Skip to main content

Security report for biogen.ch

Biogen Switzerland AG · Healthcare · Switzerland

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

81/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Switzerland AG operates as a leading biotechnology company focused on pioneering scientific research and innovation in complex and severe diseases, particularly in neurology, neuropsychiatry, immunology, and rare diseases. The website reflects a strong market position with a comprehensive product portfolio and a clear commitment to improving health outcomes. The digital infrastructure is built on Adobe Experience Manager, leveraging modern web technologies including Cookiebot for privacy compliance and Google Analytics for user insights. The site is well-optimized for mobile and accessibility, with consistent branding and professional content presentation. Security posture is solid with HTTPS enforcement and secure cookie practices, though explicit security policies and incident response contacts are not publicly disclosed. Overall, the website demonstrates a mature digital presence aligned with corporate standards and regulatory compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.ch

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
83
Average
81

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Switzerland AG targets healthcare professionals, patients, and career seekers within Switzerland, offering specialized therapies in neurology and rare diseases. The business model centers on pharmaceutical R&D with a global footprint supported by localized websites. The company maintains a strong partnership ecosystem and social media presence, enhancing brand trust and engagement. Growth indicators include active research pipelines and public engagement in events like CYBATHLON 2024. The website's multilingual support and detailed product and corporate information reflect strategic market positioning and customer-centric communication.

Security posture

The website employs HTTPS with secure cookie flags and integrates a robust cookie consent mechanism via Cookiebot, indicating compliance with GDPR and privacy best practices. However, the absence of a dedicated security policy page, incident response contact details, and a security.txt file suggests room for improvement in transparency and readiness. No vulnerabilities or exposed sensitive data were detected in the analysis. The use of third-party scripts like Google Analytics and eyeAble accessibility plugin is managed with user consent. Security headers beyond standard HTTPS are not explicitly identified, recommending enhancement to mitigate advanced threats.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Provide clear incident response contact channels such as security@ or abuse@ email addresses.
  3. Implement and enforce additional security headers like Content-Security-Policy and Strict-Transport-Security.
  4. Regularly review and update third-party scripts to minimize vulnerability exposure.
  5. Consider publishing a security.txt file to facilitate responsible vulnerability disclosure.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Switzerland AG
Description
Biogen ist eines der weltweit führenden Biotechnologie-Unternehmen. Wir leisten Pionierarbeit in der Wissenschaft und treiben Innovationen für komplexe und schwere Erkrankungen voran. Unsere Forschungspipeline umfasst Wirkstoffkandidaten in den Bereichen Neurologie, Neuropsychiatrie, Immunologie und seltene Krankheiten. Damit wollen wir einen Beitrag leisten für eine gesündere, nachhaltigere und gerechtere Welt.
Key services
Research and development of drugs for neurology, neuropsychiatry, immunology, and rare diseases
Content quality
excellent
Branding
consistent

Technology

Stack
Adobe Helix RUM, jQuery 3.6.4, Cookiebot, Google Tag Manager, Google Analytics, video.js, eyeAble accessibility plugin
Frameworks
Adobe Experience Manager (AEM)
Platforms
Adobe Experience Manager
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly and Secure flags on cookies
  • Cookie consent management implemented

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Comprehensive cookie consent mechanism implemented via Cookiebot.
  3. Strong corporate branding and consistent multilingual support (German and French).
  4. No direct email or phone contact information found on homepage; contact form is primary contact method.
  5. Use of modern web technologies and Adobe Experience Manager CMS.
  6. Social media presence on major platforms with official links.
  7. No explicit security policy or incident response information publicly available.
  8. No vulnerability disclosure or security.txt file found.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS, ensuring scalability and content management efficiency. It uses modern JavaScript libraries including jQuery 3.6.4 and video.js for media handling. Cookiebot manages cookie consent, enhancing privacy compliance. Google Tag Manager and Google Analytics provide analytics capabilities. The site is mobile-optimized and includes accessibility features via the eyeAble plugin. Performance is moderate, with potential for optimization in loading times. The technical stack is modern and well-integrated, supporting a professional and user-friendly experience. Opportunities exist to enhance security headers and streamline third-party script management.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.ch. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.ch.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.